Live Breaking News & Updates on Mnov

Stay informed with the latest breaking news from Mnov on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Mnov and stay connected to the pulse of your community

MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com

StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Get Rating) in a research note issued to investors on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock. MediciNova Trading Down 0.4 % Shares of NASDAQ MNOV opened at $2.30 on Tuesday. The business’s 50 day moving average price is $2.22 and […]

Virtu-financial , Capricorn-fund-managers-ltd , Squarepoint-ops , Medicinova-inc , Morgan-stanley , Get-rating , Nova-trading-down , Point-capital-management , Medicinova-daily , Medicinova , Nasdaq-mnov

MediciNova (NASDAQ:MNOV) Shares Pass Above 200-Day Moving Average of $2.24

MediciNova, Inc. (NASDAQ:MNOV – Get Rating) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.24 and traded as high as $2.24. MediciNova shares last traded at $2.24, with a volume of 117,638 shares. Wall Street Analyst Weigh In Separately, StockNews.com initiated coverage on […]

Medicinova-inc , Dimensional-fund-advisors , Virtu-financial , Nasdaq , Capricorn-fund-managers-ltd , Get-rating , Nova-trading-down , Street-group , Fund-managers-ltd , Fund-advisors , Medicinova-daily

First Bancorp of Indiana (OTCMKTS:FBPI) Trading Down 6%

Investment analysts at StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV – Get Rating) in a research report issued to clients and investors on Tuesday. The firm set a “hold” rating on the biopharmaceutical company’s stock. MediciNova Stock Performance Shares of NASDAQ MNOV opened at $2.29 on Tuesday. MediciNova has a twelve month low of […]

Capricorn-fund-managers-ltd , Morgan-stanley , Medicinova-inc , Squarepoint-ops , Virtu-financial , Get-rating , Point-capital-management , Medicinova-daily , Medicinova , Nasdaq-mnov , Mnov

MediciNova (NASDAQ:MNOV) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of MediciNova (NASDAQ:MNOV – Get Rating) in a research note published on Tuesday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. MediciNova Stock Performance Shares of MNOV opened at $2.30 on Tuesday. MediciNova has a 12-month low of $1.89 and a 12-month high of $3.18. The business’s […]

Dimensional-fund-advisors , Capricorn-fund-managers-ltd , Medicinova-inc , Virtu-financial , Get-rating , Street-group , Fund-managers-ltd , Fund-advisors , Medicinova-daily , Medicinova , Nasdaq-mnov

MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Get Rating) in a research report sent to investors on Monday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock. MediciNova Price Performance Shares of NASDAQ:MNOV opened at $2.10 on Monday. The stock’s 50-day simple moving average is $2.26 and its two-hundred day […]

United-states , America , Renaissance-technologies , Jpmorgan-chase-co , America-corp , Nasdaq , Medicinova-inc , Get-rating , Street-group , Street-corp , Medicinova-daily

MediciNova (NASDAQ:MNOV) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of MediciNova (NASDAQ:MNOV – Get Rating) in a research report report published on Sunday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. MediciNova Price Performance MNOV stock opened at $2.17 on Friday. MediciNova has a 1-year low of $1.89 and a 1-year high of $3.18. The business’s […]

United-states , America , Geode-capital-management , America-corp , Medicinova-inc , Jpmorgan-chase-co , Get-rating , Capital-management , Street-group , Medicinova-daily , Medicinova

MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of MediciNova (NASDAQ:MNOV – Get Rating) in a research report released on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. MediciNova Trading Down 0.9 % Shares of NASDAQ:MNOV opened at $2.17 on Friday. The company has a fifty day moving average of $2.28 and a […]

Medicinova-inc , Renaissance-technologies , Nasdaq , Morgan-stanley , Jpmorgan-chase-co , Medicinova-company-profile , Geode-capital-management , Get-rating , Nova-trading-down , Capital-management , Street-corp

FY2024 Earnings Estimate for MediciNova, Inc. (NASDAQ:MNOV) Issued By B. Riley

MediciNova, Inc. (NASDAQ:MNOV – Get Rating) – B. Riley upped their FY2024 earnings per share (EPS) estimates for shares of MediciNova in a research note issued to investors on Thursday, December 15th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will earn ($0.36) per share for the year, up from their prior […]

United-states , Jpmorgan-chase-co , Medicinova-company-profile , Renaissance-technologies , Medicinova-inc , Nasdaq , Get-rating , Street-corp , Medicinova-daily , Medicinova , Nasdaq-mnov

-$0.09 Earnings Per Share Expected for MediciNova, Inc. (NASDAQ:MNOV) This Quarter

Brokerages expect MediciNova, Inc. (NASDAQ:MNOV – Get Rating) to post earnings per share of ($0.09) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for MediciNova’s earnings. MediciNova reported earnings of ($0.07) per share during the same quarter last year, which indicates a negative year over year growth rate […]

Northern-trust-corp , Marshall-wace , Zacks-investment-research , Millennium-management , Medicinova-inc , Nasdaq , Get-rating , Zacks-investment , Investment-research , Strategic-partners , Trust-corp

KemPharm Scores FDA Nod For ADHD Drug, MNOV Quits COVID-19 Vaccine Race, UTHR Gives Up On Trevyent

(2)
NEW YORK CITY (dpa-AFX) - Today's Daily Dose brings you news about KemPharm scoring regulatory nod for its ADHD drug, expanded FDA approval for Pfizer's Lorbrena, United Therapeutics scrapping the development of Trevyent, Vir Biotechnology closing the enrollment in VIR-7831 arm of ACTIV-3 trial, and Takeda securing global rights to Ovid's investigational medicine Soticlestat.
Read on.
1.KemPharm Scores FDA Nod For ADHD Drug
KemPharm Inc. (KMPH) soared more than 42% on Wednesday, following FDA approval of AZSTARYS (formerly referred to as KP415), a once-daily product for the treatment of attention deficit hyperactivity disorder (ADHD) in patients age six years and older.

India , Japan , Bharat , Takeda-shonan , Johnson-concerta , Ovid-soticlestat , Vir-biotechnology-inc , Glaxosmithkline , Magenta-therapeutics-inc , Corium-inc , Ocugen-inc , Pfizer